Impact of multivessel disease on infarct size among STEMI patients undergoing primary angioplasty
Abstract: Background: Although primary angioplasty achieves Thrombolysis In Myocardial Infarction (TIMI) 3 flow in most patients with ST-elevation myocardial infarction, epicardial recanalization does not guarantee optimal perfusion in a large proportion of patients. Multivessel disease has been demonstrated to be associated with impaired survival, however its impact on infarct size has not been largely investigated, that therefore is the aim of the current study.Methods: Our population is represented by 827 STEMI patients undergoing primary PCI. Infarct size was evaluated at 30 days by technetium-99m-sestamibi.Results: Multivessel disease was observed in 343 patients (41.5%). It was associated with older age (65 [57–74] vs 63 [53–71], p 3 h (63.7% vs 56.4%, p = 0.038), and a trend in more cardiogenic shock (5.5% vs 2.9%, p = 0.055). Patients with multivessel disease received more often Abciximab (92.1% vs 88.4%, p
Source: Atherosclerosis - Category: Cardiology Authors: Giuseppe De Luca, Guido Parodi, Roberto Sciagrà, Benedetta Bellandi, Vincenzo Comito, Ruben Vergara, Angela Migliorini, Renato Valenti, David Antoniucci Tags: Clinical & Population Research – Intervention Source Type: research
More News: Abciximab | Angioplasty | Cardiogenic Shock | Cardiology | Heart | Heart Attack | Perfusion | Study